Condition: Urothelial Carcinoma · Advanced Urothelial Carcinoma · Urothelial Carcinoma Recurrent · Sponsor: Sun Yat-sen University
This is a multicenter, open-label, Phase II clinical trial to evaluate the efficacy and safety of Trastuzumab Rezetecan (SHR-A1811) or in combination with Adebrelimab (SHR-1316) for HER2-expressing locally advanced or metastatic urothelial carcinoma (la/mUC).
This description comes directly from the study's public registry record.
Yanxia Shi, Doctor · 86-020-87343486 · shiyx@sysucc.org.cn
Haifeng Li, Doctor · 86-020-87343486 · lihf@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Sun yat-sen university cancer center | Guangzhou, Guangdong, China | Recruiting |
| The fifth Affiliated Hospital of Guangzhou Medcial University | Guangzhou, Guangdong, China | Recruiting |
| Tongji Hospital, Affiliated to Tongji Medical College of Huazhong University of Science and Technology | Wuhan, Hubei, China | Not Yet Recruiting |
| Jiangxi Cancer Center | Nanchang, Jiangxi, China | Recruiting |
| The Second Affiliated Hospital of Kunming Medical University | Kunming, Yunnan, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07241793